Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech CEO Expects To Modify COVID-19 Vaccine To Omicron Variant

12/03/2021 | 06:42am EST


© MT Newswires 2021
All news about BIONTECH SE
01/14Omicron leaves Germany on brink of recession as growth dips
AQ
01/14German economy short of pre-pandemic level despite 2.7% growth in 2021
RE
01/13European ADRs Move Higher in Thursday Trading
MT
01/13Acuitas Therapeutics Names Miranda Lam as
AQ
01/13Positive Top-Line Results of Pfizer's Phase 3 Study Exploring Coadministration of PREVN..
AQ
01/13WHO, EMA Warn Against Repeated COVID-19 Booster Shots
MT
01/12Pfizer's Pneumonia Jab, COVID-19 Booster Shot Safe for Coadministration in Late-Stage S..
MT
01/12BIONTECH : Goldman Sachs reaffirms its Neutral rating
MD
01/12Pfizer Says Pneumococcal Vaccine Combined with COVID-19 Shot Effective in Adults Above ..
MT
01/12Pfizer Reports Positive Results From Study Co-Administering Vaccines for Covid-19, Pneu..
DJ
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 437 M 19 903 M 19 903 M
Net income 2021 9 220 M 10 523 M 10 523 M
Net cash 2021 8 905 M 10 164 M 10 164 M
P/E ratio 2021 4,68x
Yield 2021 -
Capitalization 41 474 M 47 338 M 47 338 M
EV / Sales 2021 1,87x
EV / Sales 2022 1,42x
Nbr of Employees 2 800
Free-Float -
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 171,72 €
Average target price 264,52 €
Spread / Average Target 54,0%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-23.97%47 338
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS, INC.-2.58%64 327
VERTEX PHARMACEUTICALS INCORPORATED6.58%59 510
WUXI APPTEC CO., LTD.-3.88%52 722
BEIGENE, LTD.-11.92%24 519